Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and/or female subjects with hemophilia B.~* Subjects/parents/legal representatives must be able to comply with study procedures (informed consent/assent process, clinical visits, reporting of infusion and bleed data, reporting of adverse events, etc)~Exclusion Criteria:~* Presence of any other bleeding disorder in addition to hemophilia B. Subjects with a past history of, or current factor IX inhibitor. For laboratory-based assessments, any Bethesda inhibitor titer greater than the laboratory's normal range or ≥0.6 Bethesda Unit (BU)/mL.~* Subjects with known hypersensitivity to the active substance or to any of the excipients of BeneFIX.~* Subjects with a known hypersensitivity to Chinese Hamster Ovary cell proteins.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Benefix (Type: EXPERIMENTAL): This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.

Based on this trial design, predict the completion outcome and termination type (if applicable).